Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021

Agam K Rao, Jeremy Sobel, Kevin Chatham-Stephens, Carolina Luquez, Agam K Rao, Jeremy Sobel, Kevin Chatham-Stephens, Carolina Luquez

Abstract

Botulism is a rare, neurotoxin-mediated, life-threatening disease characterized by flaccid descending paralysis that begins with cranial nerve palsies and might progress to extremity weakness and respiratory failure. Botulinum neurotoxin, which inhibits acetylcholine release at the neuromuscular junction, is produced by the anaerobic, gram-positive bacterium Clostridium botulinum and, rarely, by related species (C. baratii and C. butyricum). Exposure to the neurotoxin occurs through ingestion of toxin (foodborne botulism), bacterial colonization of a wound (wound botulism) or the intestines (infant botulism and adult intestinal colonization botulism), and high-concentration cosmetic or therapeutic injections of toxin (iatrogenic botulism). In addition, concerns have been raised about the possibility of a bioterrorism event involving toxin exposure through intentional contamination of food or drink or through aerosolization. Neurologic symptoms are similar regardless of exposure route. Treatment involves supportive care, intubation and mechanical ventilation when necessary, and administration of botulinum antitoxin. Certain neurological diseases (e.g., myasthenia gravis and Guillain-Barré syndrome) have signs and symptoms that overlap with botulism. Before the publication of these guidelines, no comprehensive clinical care guidelines existed for treating botulism. These evidence-based guidelines provide health care providers with recommended best practices for diagnosing, monitoring, and treating single cases or outbreaks of foodborne, wound, and inhalational botulism and were developed after a multiyear process involving several systematic reviews and expert input.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE 1
FIGURE 1
Assessing patients with known or possible exposure to botulinum toxin in conventional and contingency settings* * When assessing the likelihood of botulism, consider clinical criteria and available epidemiologic data. Classify patients into a botulism likelihood category per the clinician’s judgement. Additional information on clinical criteria is available (Rao AK, Lin NH, Griese SE, Chatham-Stephens K, Badell ML, Sobel J. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks. Clin Infect Dis 2017;66[suppl_1]:S38–S42).
FIGURE 2
FIGURE 2
Assessing patients with known or possible exposure to botulinum toxin in crisis settings* * When assessing the likelihood of botulism, consider clinical criteria and available epidemiologic data. Classify patients into a botulism likelihood category per the clinician’s judgement. Additional information on clinical criteria is available (Rao AK, Lin NH, Griese SE, Chatham-Stephens K, Badell ML, Sobel J. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks. Clin Infect Dis 2017;66[suppl_1]:S38–S42).

References

    1. Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ. Wound botulism in California, 1951–1998: recent epidemic in heroin injectors. Clin Infect Dis 2000;31:1018–24. 10.1086/318134
    1. Arnon SS, Schechter R, Inglesby TV, et al.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059–70. 10.1001/jama.285.8.1059
    1. Sobel J. Botulism. Clin Infect Dis 2005;41:1167–73. 10.1086/444507
    1. Smith LD. Botulism. The organism, its toxins, the disease. Springfield, IL: Charles C. Thomas; 1977.
    1. Dack GM, Wood WL. Serum therapy of botulism in monkeys. J Infect Dis 1928;42:209–12. 10.1093/infdis/42.3.209
    1. Ono T, Karashimada T, Iida H. Studies of the serum therapy of type E botulism. 3. Jpn J Med Sci Biol 1970;23:177–91. 10.7883/yoken1952.23.177
    1. Morton HE. The toxicity of Clostridium botulinum type A toxin for various species of animals, including man. Philadelphia, PA: Institute for Cooperative Research, University of Pennsylvania; 1961.
    1. Maslanka SE, Lúquez C, Dykes JK, et al. A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J Infect Dis 2016;213:379–85. 10.1093/infdis/jiv327
    1. Zhang S, Masuyer G, Zhang J, et al. Identification and characterization of a novel botulinum neurotoxin. Nat Commun 2017;8:14130. 10.1038/ncomms14130
    1. Zhang S, Lebreton F, Mansfield MJ, et al. Identification of a botulinum neurotoxin-like toxin in a commensal strain of Enterococcus faecium. Cell Host Microbe 2018;23:169–176.e6. 10.1016/j.chom.2017.12.018
    1. Brunt J, Carter AT, Stringer SC, Peck MW. Identification of a novel botulinum neurotoxin gene cluster in Enterococcus. FEBS Lett 2018;592:310–7. 10.1002/1873-3468.12969
    1. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82:427–46. 10.1016/S0300-9084(00)00216-9
    1. Rao AK, Lin NH, Jackson KA, Mody RK, Griffin PM. Clinical characteristics and ancillary test results among patients with botulism—United States, 2002–2015. Clin Infect Dis 2017;66(suppl_1):S4–10. 10.1093/cid/cix935
    1. Chatham-Stephens K, Fleck-Derderian S, Johnson SD, Sobel J, Rao AK, Meaney-Delman D. Clinical features of foodborne and wound botulism: a systematic review of the literature, 1932–2015. Clin Infect Dis 2017;66(suppl_1):S11–6. 10.1093/cid/cix811
    1. Caleo M, Restani L. Exploiting botulinum neurotoxins for the study of brain physiology and pathology. Toxins (Basel) 2018;10:175. 10.3390/toxins10050175
    1. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95:442–5. 10.7326/0003-4819-95-4-442
    1. Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J Infect Dis 1992;166:1281–6. 10.1093/infdis/166.6.1281
    1. Demarchi J, Mourgues C, Orio J, Prevot AR. [Existence of type D botulism in man]. Bull Acad Natl Med 1958;142:580–2.
    1. Prevot AR, Sillioc R. [Biological enigma: cat and botulism]. Ann Inst Pasteur (Paris) 1955;89:354–7.
    1. Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, Simpson LL. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther 1997;280:1489–98.
    1. Eleopra R, Tugnoli V, Quatrale R, et al. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol 2002;113:1258–64. 10.1016/S1388-2457(02)00103-7
    1. Rogers DE, Koenig MG, Spickard A. Clinical and laboratory manifestations of type E botulism in man. Trans Assoc Am Physicians 1964;77:135–44.
    1. Dolman CE. Further outbreaks of botulism in Canada. Can Med Assoc J 1961;84:191–200.
    1. Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J. Adult botulism type F in the United States, 1981–2002. Neurology 2005;65:1694–700. 10.1212/01.wnl.0000187127.92446.4c
    1. Sobel J, Dill T, Kirkpatrick CL, Riek L, Luedtke P, Damrow TA. Clinical recovery and circulating botulinum toxin type F in adult patient. Emerg Infect Dis 2009;15:969–71. 10.3201/eid1506.070571
    1. Sobel J, Rao AK. Making the best of the evidence: toward national clinical guidelines for botulism. Clin Infect Dis 2017;66(suppl_1):S1–3. 10.1093/cid/cix829
    1. Fleck-Derderian S, Shankar M, Rao AK, et al. The epidemiology of foodborne botulism outbreaks: a systematic review. Clin Infect Dis 2017;66(suppl_1):S73–81. 10.1093/cid/cix846
    1. O’Horo JC, Harper EP, El Rafei A, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923–2016. Clin Infect Dis 2017;66(suppl_1):S43–56. 10.1093/cid/cix815
    1. Schussler E, Sobel J, Hsu J, et al. Workgroup report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup—Allergic reactions to botulinum antitoxin: a systematic review. Clin Infect Dis 2017;66(suppl_1):S65–72. 10.1093/cid/cix827
    1. Badell ML, Rimawi BH, Rao AK, Jamieson DJ, Rasmussen S, Meaney-Delman D. Botulism during pregnancy and the postpartum period: a systematic review. Clin Infect Dis 2017;66(suppl_1):S30–7. 10.1093/cid/cix813
    1. Griese SE, Kisselburgh HM, Bartenfeld MT, et al. Pediatric botulism and use of equine botulinum antitoxin in children: a systematic review. Clin Infect Dis 2017;66(suppl_1):S17–29. 10.1093/cid/cix812
    1. Halpin AL, Khouri JM, Payne JR, et al. Type F infant botulism: investigation of recent clusters and overview of this exceedingly rare disease. Clin Infect Dis 2017;66(suppl_1):S92–4. 10.1093/cid/cix818
    1. Jacobs Slifka K, Harris JA, Nguyen V, Luquez C, Tiwari T, Rao AK. A case of localized, unilateral (cephalic) wound botulism. Clin Infect Dis 2017;66(suppl_1):S95–8. 10.1093/cid/cix828
    1. Parameswaran L, Rao A, Chastain K, et al. A case of adult intestinal toxemia botulism during prolonged hospitalization in an allogeneic hematopoietic cell transplant recipient. Clin Infect Dis 2017;66(suppl_1):S99–102. 10.1093/cid/cix847
    1. Harvey RR, Cooper R, Bennett S, et al. Outbreak of foodborne botulism in an immigrant community: Overcoming delayed disease recognition, ambiguous epidemiologic links, and cultural barriers to identify the cause. Clin Infect Dis 2017;66(suppl_1):S82–4. 10.1093/cid/cix817
    1. Rao AK, Lin NH, Griese SE, Chatham-Stephens K, Badell ML, Sobel J. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks. Clin Infect Dis 2017;66(suppl_1):S38–42. 10.1093/cid/cix814
    1. Yu PA, Lin NH, Mahon BE, et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis 2017;66(suppl_1):S57–64. 10.1093/cid/cix816
    1. Rao AK, Walters M, Hall J, et al. Outbreak of botulism due to illicit prison-brewed alcohol: public health response to a serious and recurrent problem. Clin Infect Dis 2017;66(suppl_1):S85–91. 10.1093/cid/cix936
    1. Committee on Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations; Institute of Medicine. Crisis standards of care: a systems framework for catastrophic disaster response. National Academies Press: Washington, DC; 2012.
    1. Hick JL, Barbera JA, Kelen GD. Refining surge capacity: conventional, contingency, and crisis capacity. Disaster Med Public Health Prep 2009;3(Suppl 2):S59–67. 10.1097/DMP.0b013e31819f1ae2
    1. Institute of Medicine. Crisis standards of care: a toolkit for indicators and triggers. Washington, DC: National Academies Press; 2013.
    1. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221–8. 10.7326/0003-4819-129-3-199808010-00011
    1. Maslanka S, Agam KR. Botulism. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. Harrison’s principles of internal medicine, 19th ed. New York, NY: McGraw-Hill Education; 2015.
    1. Sheth AN, Wiersma P, Atrubin D, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008;47:1245–51. 10.1086/592574
    1. Sobel J. Diagnosis and treatment of botulism: a century later, clinical suspicion remains the cornerstone. Clin Infect Dis 2009;48:1674–5. 10.1086/599030
    1. St Louis ME, Peck SH, Bowering D, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med 1988;108:363–8. 10.7326/0003-4819-108-3-363
    1. Filozov A, Kattan JA, Jitendranath L, et al. Asymmetric type F botulism with cranial nerve demyelination. Emerg Infect Dis 2012;18:102–4. 10.3201/eid1801.110471
    1. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014;137:33–43. 10.1093/brain/awt285
    1. Mallik A, Weir AI. Nerve conduction studies: essentials and pitfalls in practice. J Neurol Neurosurg Psychiatry 2005;76(Suppl 2):ii23–31. 10.1136/jnnp.2005.069138
    1. Maselli RA, Bakshi N; American Association of Electrodiagnostic Medicine. AAEM case report 16. Botulism. Muscle Nerve 2000;23:1137–44. 10.1002/1097-4598(200007)23:7<1137::AID-MUS21>;2-7
    1. Maselli RA, Ellis W, Mandler RN, et al. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997;20:1284–95. 10.1002/(SICI)1097-4598(199710)20:10<1284::AID-MUS11>;2-3
    1. Padua L, Aprile I, Monaco ML, et al. Neurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG. Muscle Nerve 1999;22:1388–92. 10.1002/(SICI)1097-4598(199910)22:10<1388::AID-MUS8>;2-3
    1. McCarty CL, Angelo K, Beer KD, et al. Large outbreak of botulism associated with a church potluck meal—Ohio, 2015. MMWR Morb Mortal Wkly Rep 2015;64:802–3. 10.15585/mmwr.mm6429a6
    1. Maslanka SE, Solomon HM, Sharma S, Johnson EA. Chapter 32. Clostridium botulinum and its toxins. In: Salfinger Y, Tortorello ML, eds. Compendium of methods for the microbiological examination of foods: Washington, DC: American Public Health Association Press; 2013.
    1. Kalb SR, Baudys J, Wang D, Barr JR. Recommended mass spectrometry-based strategies to identify botulinum neurotoxin-containing samples. Toxins (Basel) 2015;7:1765–78. 10.3390/toxins7051765
    1. Mighty HE. Acute respiratory failure in pregnancy. Clin Obstet Gynecol 2010;53:360–8. 10.1097/GRF.0b013e3181deb3f1
    1. Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001;120:562–6. 10.1378/chest.120.2.562
    1. Wongtanate M, Sucharitchan N, Tantisiriwit K, et al. Signs and symptoms predictive of respiratory failure in patients with foodborne botulism in Thailand. Am J Trop Med Hyg 2007;77:386–9. 10.4269/ajtmh.2007.77.386
    1. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58:893–8. 10.1001/archneur.58.6.893
    1. Stefanutti D, Fitting J-W. Sniff nasal inspiratory pressure. Reference values in Caucasian children. Am J Respir Crit Care Med 1999;159:107–11. 10.1164/ajrccm.159.1.9804052
    1. Uldry C, Fitting JW. Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax 1995;50:371–5. 10.1136/thx.50.4.371
    1. Laveneziana P, Albuquerque A, Aliverti A, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J 2019;53:1801214. 10.1183/13993003.01214-2018
    1. Héritier F, Rahm F, Pasche P, Fitting JW. Sniff nasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med 1994;150:1678–83. 10.1164/ajrccm.150.6.7952632
    1. Elsheikh B, Arnold WD, Gharibshahi S, Reynolds J, Freimer M, Kissel JT. Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. Muscle Nerve 2016;53:134–6. 10.1002/mus.24929
    1. Harms M. Inpatient management of Guillain-Barré syndrome. Neurohospitalist 2011;1:78–84. 10.1177/1941875210396379
    1. Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol 2008;8:229–37. 10.1136/pn.2008.152611
    1. Hughes RA, Bihari D. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry 1993;56:334–43. 10.1136/jnnp.56.4.334
    1. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34–8. 10.1159/000067023
    1. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13(Suppl 4):1–9. 10.1111/j.1468-1331.2006.01648.x
    1. Jenzer G, Mumenthaler M, Ludin HP, Robert F. Autonomic dysfunction in botulism B: a clinical report. Neurology 1975;25:150–3. 10.1212/WNL.25.2.150
    1. Koenig MG, Drutz DJ, Mushlin AI, Schaffner W, Rogers DE. Type B botulism in man. Am J Med 1967;42:208–19. 10.1016/0002-9343(67)90020-4
    1. Merz B, Bigalke H, Stoll G, Naumann M. Botulism type B presenting as pure autonomic dysfunction. Clin Auton Res 2003;13:337–8. 10.1007/s10286-003-0118-2
    1. Potulska-Chromik A, Zakrzewska-Pniewska B, Szmidt-Sałkowska E, et al. Long lasting dysautonomia due to botulinum toxin B poisoning: clinical-laboratory follow up and difficulties in initial diagnosis. BMC Res Notes 2013;6:438. 10.1186/1756-0500-6-438
    1. Truax BT, ed. Autonomic disturbances in the Guillain-Barré syndrome. Seminars in Neurology; 1984: Thieme Medical Publishers, Inc.
    1. Dalos NP, Borel C, Hanley DF. Cardiovascular autonomic dysfunction in Guillain-Barré syndrome. Therapeutic implications of Swan-Ganz monitoring. Arch Neurol 1988;45:115–7. 10.1001/archneur.1988.00520250125034
    1. Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM. Intensive management and treatment of severe Guillain-Barré syndrome. Crit Care Med 1993;21:433–46. 10.1097/00003246-199303000-00023
    1. Hughes RA, Wijdicks EF, Benson E, et al.; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62:1194–8. 10.1001/archneur.62.8.1194
    1. Rabinstein AA. Acute neuromuscular respiratory failure. Continuum (Minneap Minn) 2015;21(5 Neurocritical Care):1324–45. 10.1212/CON.0000000000000218
    1. Fiz JA, Haro M, Aguilar J, et al. Spirometry and maximal respiratory pressures in patients with facial paralysis. Chest 1993;103:170–3. 10.1378/chest.103.1.170
    1. Cabrera Serrano M, Rabinstein AA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol 2010;67:1089–94. 10.1001/archneurol.2010.207
    1. Mangera Z, Panesar G, Makker H. Practical approach to management of respiratory complications in neurological disorders. Int J Gen Med 2012;5:255–63.
    1. O’Horo JC, Harper EP, El Rafei A, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923–2016. Clin Infect Dis 2017;66(suppl_1):S43–56. 10.1093/cid/cix815
    1. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794–8. 10.1016/0002-9343(84)90988-4
    1. Botulism antitoxin heptavalent. (A, B, C, D, E, F, G)—(Equine) [package insert]. Gaithersburg, MD: Cangene Corporation (as Emergent Biosolutions); 2017.
    1. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980;69:567–70. 10.1016/0002-9343(80)90469-6
    1. Kongsaengdao S, Samintarapanya K, Rusmeechan S, et al.; Thai Botulism Study Group. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis 2006;43:1247–56. 10.1086/508176
    1. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984;150:407–12. 10.1093/infdis/150.3.407
    1. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462–71. 10.1056/NEJMoa051926
    1. Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth 1997;78:601–5. 10.1093/bja/78.5.601
    1. Feng L, Chen X, Liu S, Zhou Z, Yang R. Two-family outbreak of botulism associated with the consumption of smoked ribs in Sichuan Province, China. Int J Infect Dis 2015;30:74–7. 10.1016/j.ijid.2014.10.008
    1. Gomez HF, Johnson R, Guven H, et al. Adsorption of botulinum toxin to activated charcoal with a mouse bioassay. Ann Emerg Med 1995;25:818–22. 10.1016/S0196-0644(95)70214-8
    1. Osterhoudt KC, Alpern ER, Durbin D, Nadel F, Henretig FM. Activated charcoal administration in a pediatric emergency department. Pediatr Emerg Care 2004;20:493–8. 10.1097/01.pec.0000136064.14704.d1
    1. Mazuet C, Dano J, Popoff MR, Créminon C, Volland H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One 2010;5:e12416. 10.1371/journal.pone.0012416
    1. Cherington M, Ryan DW. Botulism and guanidine. N Engl J Med 1968;278:931–3. 10.1056/NEJM196804252781704
    1. Cherington M, Ryan DW. Treatment of botulism with guanidine. Early neurophysiologic studies. N Engl J Med 1970;282:195–7. 10.1056/NEJM197001222820405
    1. Puggiari M, Cherington M. Botulism and guanidine. Ten years later. JAMA 1978;240:2276–7. 10.1001/jama.1978.03290210058027
    1. Kaplan JE, Davis LE, Narayan V, Koster J, Katzenstein D. Botulism, type A, and treatment with guanidine. Ann Neurol 1979;6:69–71. 10.1002/ana.410060117
    1. Davis LE, Johnson JK, Bicknell JM, Levy H, McEvoy KM. Human type A botulism and treatment with 3,4-diaminopyridine. Electromyogr Clin Neurophysiol 1992;32:379–83.
    1. Faich GA, Graebner RW, Sato S. Failure of guanidine therapy in botulism A. N Engl J Med 1971;285:773–6. 10.1056/NEJM197109302851404
    1. Oh SJ, Halsey JH Jr, Briggs DDJ Jr. Guanidine in type B botulism. Arch Intern Med 1975;135:726–8. 10.1001/archinte.135.5.726
    1. Ball AP, Hopkinson RB, Farrell ID, et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979;48:473–91.
    1. Paterson DL, King MA, Boyle RS, et al. Severe botulism after eating home-preserved asparagus. Med J Aust 1992;157:269–70. 10.5694/j.1326-5377.1992.tb137135.x
    1. Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother 2003;37:127–31. 10.1345/aph.1C034
    1. Wang YC, Burr DH, Korthals GJ, Sugiyama H. Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism. Appl Environ Microbiol 1984;48:951–5. 10.1128/AEM.48.5.951-955.1984
    1. Molgó J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987;10:464–70. 10.1002/mus.880100514
    1. L’Hommedieu C, Stough R, Brown L, Kettrick R, Polin R. Potentiation of neuromuscular weakness in infant botulism by aminoglycosides. J Pediatr 1979;95:1065–70. 10.1016/S0022-3476(79)80314-5
    1. Paradelis AG, Triantaphyllidis C, Giala MM. Neuromuscular blocking activity of aminoglycoside antibiotics. Methods Find Exp Clin Pharmacol 1980;2:45–51.
    1. Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981;68:50–4.
    1. Lee JH, Lee SI, Chung CJ, et al. The synergistic effect of gentamicin and clindamycin on rocuronium-induced neuromuscular blockade. Korean J Anesthesiol 2013;64:143–51. 10.4097/kjae.2013.64.2.143
    1. Rhee WJ, Lee SY, Lee JH, et al. The effect of high concentration of magnesium with ropivacaine, gentamicin, rocuronium, and their combination on neuromuscular blockade. Korean J Anesthesiol 2015;68:50–61. 10.4097/kjae.2015.68.1.50
    1. Pandian SJ, Subramanian M, Vijayakumar G, Balasubramaniam GA, Sukumar K. Therapeutic management of botulism in dairy cattle. Vet World 2015;8:1305–9.
    1. Del Pozo E, Baeyens JM. Effects of calcium channel blockers on neuromuscular blockade induced by aminoglycoside antibiotics. Eur J Pharmacol 1986;128:49–54. 10.1016/0014-2999(86)90556-X
    1. Paradelis AG, Triantaphyllidis CJ, Mironidou M, Crassaris LG, Karachalios DN, Giala MM. Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions. Methods Find Exp Clin Pharmacol 1988;10:687–90.
    1. Simpson LL. The interaction between 5-hydroxytryptamine and botulinum toxin type A. Toxicol Appl Pharmacol 1968;12:249–59. 10.1016/0041-008X(68)90037-9
    1. Hale TW. Maternal medications during breastfeeding. Clin Obstet Gynecol 2004;47:696–711. 10.1097/01.grf.0000135653.56778.3f
    1. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167–93. 10.1146/annurev.pharmtox.44.101802.121554
    1. Middaugh J. Botulism and breast milk. N Engl J Med 1978;298:343. 10.1056/NEJM197802092980620
    1. Jim J, Johnson B, Millerburg T, Silver T, Funk D, Bixby M. Type A botulism in Alaska. State of Alaska Epidemiology Bulletin. 1976;13.
    1. Douthirt C. An outbreak of botulism in Tucumcari, New Mexico. Southwest Med 1938;(2):51–3.
    1. CDC. Botulism—California. MMWR Morb Mortal Wkly Rep 1972;21:106.
    1. Moodley A, Quinlisk P, Garvey A, Kalas N, Barash JR, Khouri JM. Notes from the field: infant botulism caused by Clostridium baratii type F—Iowa, 2013. MMWR Morb Mortal Wkly Rep 2015;64:400.
    1. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA; Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol 2010;31:319–26. 10.1086/651091
    1. Berlowitz D, VanDeusen Lukas C, Parker V, Niederhauser A, Silver J, Logan C, et al. Preventing pressure ulcers in hospitals. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
    1. Klompas M, Branson R, Eichenwald EC, et al.; Society for Healthcare Epidemiology of America (SHEA). Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:915–36. 10.1086/677144
    1. Marcus SM. Reflections on the care of a patient severely poisoned by ‘rogue’ botulinum toxin and rendered paralysed for a protracted hospital stay. Botulinum J 2009;1:318–39. 10.1504/TBJ.2009.031683
    1. ten Hoorn S, Elbers PW, Girbes AR, Tuinman PR. Communicating with conscious and mechanically ventilated critically ill patients: a systematic review. Crit Care 2016;20:333. 10.1186/s13054-016-1483-2
    1. Cohen RE, Anderson DL. Botulism: emotional impact on patient and family. J Psychosom Res 1986;30:321–6. 10.1016/0022-3999(86)90009-7

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi